Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan

Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan

Background: Most HER2-positive breast or gastric cancers eventually become resistant to the approved anti-HER2 antibody-drug conjugates (ADC) trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd). Disitamab vedotin (DV) is a novel anti-HER2 ADC that binds to a different epitope on HER2 co...

Full description

Saved in:
Bibliographic Details
Main Authors: Negar Pourjamal, Vadim Le Joncour, György Vereb, Cilla Honkamaki, Jorma Isola, Jeffrey V Leyton, Pirjo Laakkonen, Heikki Joensuu, Mark Barok
Format: Article
Language:English
Published: Elsevier 2025-03-01
Series:Translational Oncology
Subjects:
Antibody drug conjugate
Disitamab vedotin
Human epidermal growth factor receptor 2
Trastuzumab deruxtecan
Trastuzumab emtansine
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523325000154
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items